U.S. pharma big copyright scrapped two experimental weight loss drugs last yr—a once-everyday capsule, lotiglipron, as a result of elevated liver enzymes in addition to a 2 times-each day tablet, danuglipron, because of robust side effects—but CEO Albert Bourla has reported the company is decided to “Perform and acquire” inside the being ov